Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04951804

EUS-CPN With and Without Bupivacaine

Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-04-23

180

Participants Needed

1

Research Sites

425 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Endoscopic ultrasound (EUS) allows EUS-guided trans gastric injection of absolute alcohol around the base of the celiac plexus (celiac plexus neurolysis (EUS-CPN)), to help alleviate pain associated with pancreatic cancer. It is standard procedure to inject bupivacaine immediately before injecting absolute alcohol, to theoretically prevent pain that may occur during and after the procedure. However, there are no data showing whether bupivacaine injection has any real influence on intra-procedural, immediate post-procedural, or long-term pain control. The injection of bupivacaine before the alcohol may have no effect, a synergistic effect, or an antagonistic effect, by diluting the alcohol, and reducing its neurolytic capacity. Inadvertent intravascular injection of bupivacaine may also cause irreversible cardiac arrhythmias and death. The investigators therefore propose a randomized clinical trial to determine whether the exclusion of bupivacaine during EUS-guided CPN improves outcomes, or not.

CONDITIONS

Official Title

EUS-CPN With and Without Bupivacaine

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Malignant-appearing pancreatic mass or proven pancreatic cancer involving the pancreatic genu, body, or tail
  • Any level of abdominal or back pain possibly related to the mass, including new onset pain under 3 months, constant pain, centrally located pain, with or without radiation to the back, and no other obvious pain source
  • No possibility of surgical management
  • Signed informed consent
  • Celiac axis accessible for bilateral neurolysis at endoscopic ultrasound
Not Eligible

You will not qualify if you...

  • Allergy to bupivacaine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centre de recherche du Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada, H2X 0A9

Actively Recruiting

Loading map...

Research Team

C

CHARLES MACKAY, RN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here